TY  - GEN
AU  - Ramalingam,Suresh S
AU  - Pérol,Maurice
AU  - Reck,Martin
AU  - Kowalyszyn,Ruben Dario
AU  - Gautschi,Oliver
AU  - Kimmich,Martin
AU  - Cho,Eun Kyung
AU  - Czyzewicz,Grzegorz
AU  - Grigorescu,Alexandru
AU  - Karaseva,Nina
AU  - Dakhil,Shaker
AU  - Lee,Pablo
AU  - Zimmerman,Annamaria
AU  - Sashegyi,Andreas
AU  - Alexandris,Ekaterine
AU  - Carter,Gebra Cuyun
AU  - Winfree,Katherine B
AU  - Garon,Edward B
TI  - Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial
SN  - 1938-0690
PY  - 2019///0308
KW  - Adult
KW  - Age Factors
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Carcinoma, Non-Small-Cell Lung
KW  - drug therapy
KW  - Docetaxel
KW  - Double-Blind Method
KW  - Female
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Salvage Therapy
KW  - methods
KW  - Vascular Endothelial Growth Factor Receptor-2
KW  - antagonists & inhibitors
KW  - Young Adult
KW  - Ramucirumab
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.cllc.2017.12.011
ER  -